Key result
Magnetofluid LAAO achieves durable, thrombus-free occlusion without device leakage or myocardial injury in pigs.
Why the study?
Peri-device leak and device-related thrombus remain key challenges of current left atrial appendage occlusion due to incompatibility between solid occluders and the LAA.
Does left atrial appendage occlusion using magnetofluids prevent device-related thrombus and myocardial injury compared to solid occluders in a pig model?
Does left atrial appendage occlusion using magnetofluids prevent device-related thrombus and myocardial injury compared to solid occluders in a pig model?
Magnetofluid-based LAAO provides a personalized, complete occlusion that prevents device-related thrombus and myocardial injury in a preclinical pig model.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“A striking new paper in Nature describes a radically different concept for stroke prevention in AF: injectable magnetofluids that solidify inside the left atrial appendage to create a personalised occlusion. No plug. No frame. No anchors. Just a catheter-delivered liquid that becomes a conforming gel inside the LAA.”
“In animal models, this approach showed: complete appendage filling, no peri-device leak, no device-related thrombus, smooth endocardialisation over the gel surface. Compared with the current benchmark device, the Watchman FLX, the gel formed a smoother and more complete endothelial surface.”
“This could represent a paradigm change in structural cardiology: From implanting hardware to injecting biomaterials that conform to anatomy. Interventional neuroradiology already does this with liquid embolics. Structural heart may be next.”
Magnetofluid LAA occlusion succeeds in pigs; hypothesis-generating for human AF stroke prevention, with no practice change warranted yet.
Peri-device leak and device-related thrombus1 remain key challenges of current left atrial appendage occlusion (LAAO)2 owing to the incompatibility between the solid occluder and the left atrial appendage (LAA). Here we propose a personalized and complete LAAO using magnetofluids that is suitable for all types of LAAs. Magnetofluids can be injected into LAAs from cardiac catheters. In the presence of a sufficient magnetic field, magnetofluids can resist high-speed blood flow. Magnetofluids can precipitate into magnetogels in contact with water in the blood within only a few minutes. We further confirmed the long-term resilience and biocompatibility of the magnetogel over 10 months in a pig model in vivo. Neither device-related thrombus nor magnetogel leakage was observed in any pigs. The endocardium formed on the Watchman occluder was rough and incomplete, predisposing to thrombosis. Myocardial injuries were unavoidable due to the barbs of the Watchman occluder. The endocardium formed on our magnetogel was smooth, firm and thrombus-free. No crevice was observed between our magnetogel and the LAA, and no injury was caused to the myocardium. These findings may offer a promising clinical strategy for long-term thrombus-free LAAO.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied Left atrial appendage occlusion. Magnetofluids vs. Watchman occluder was evaluated on Device-related thrombus and magnetogel leakage. Magnetofluid-based left atrial appendage occlusion resulted in a smooth, firm, and thrombus-free endocardium without device leakage or myocardial injury over 10 months in a pig model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: